San Francisco, CA-August 22, 2006 - AlloPort, a real-time, neutral B2B procurement platform purpose-built for AATB-accredited tissue banks and hospital/ASC operating room procurement teams, today announced its planned public launch on September 1, 2026, followed by its industry debut at the American Association of Tissue Banks (AATB) Annual Conference in San Francisco on October 4.
AlloPort Launches on September 1 Leveling the Playing Field for Accredited Tissue Banks and Expanding Hospital Access to Allografts
2 min read Premium comments
#allograftsAlloPortChris FureJames ForsellNikki Couloumbispublic launch
AlloPort was created for the tissue banking industry by tissue banking people. Its leadership and advisory team includes Dr. James Forsell, former Chairman of the American Association of Tissue Banks; Nikki Couloumbis, Founder of Allografts.com; and a veteran team of operators with collectively more than 100 years of healthcare experience assembled by serial entrepreneur Chris Fure.
“AlloPort exists because the tissue banking market needs a credible, industry-aligned procurement platform that expands access without disrupting the trusted role of accredited tissue banks,” said Fure, AlloPort Co-Founder & CEO. “Surgeons need better access to best-fit allografts, procurement managers need faster discovery, and tissue banks deserve a direct, efficient path to operating rooms without surrendering margin to unnecessary intermediaries.”
A Neutral Exchange — Not a Distributor
AlloPort lists inventory and processes orders, but does not hold, store, relabel, or ship allografts. Accredited tissue banks maintain custody, quality control, pricing authority, and fulfillment responsibility. AlloPort routes orders directly to the originating tissue bank for acceptance and fulfillment, while supporting accreditation visibility, state-license gating, lot/UDI traceability, document access, recall readiness, and audit-trail confirmation.
“AlloPort reflects best practices the tissue banking community has advanced for years — license eligibility, traceability, recall readiness, and procurement transparency — now made practical through a single-source procurement solution,” said Dr. Forsell, AlloPort Co-Founder & CBO (brand).
This sentiment was expanded by Couloumbis, AlloPort Co-Founder & CSO (sales): “It preserves the role of accredited banks while helping procurement managers find the right graft faster.”
Built to Work With the Systems Tissue Banks Already Use
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system. The company’s fragmented data aggregation and normalization technology was pioneered by AlloPort Co-Founder & CTO Jim Chu (founder of EMBD Finance, formerly with Cisco Systems).
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”
Moreover, surgeons benefit from expanded access to graft options that may better align with procedural requirements, patient anatomy, and scheduling demands. “This would definitely be a helpful tool,” remarked Dr Philip Omohundro, of the Centers for Advanced Orthopedics in Silver Spring, MD.
Media Contact
Mark Russo, VP Marketing
AlloPort LLC
mrusso@alloport.com +1 (415) 806-4625
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
AlloPort's strategic launch aims to transform allograft procurement by creating a neutral B2B platform connecting accredited tissue banks directly with hospitals. This model seeks to enhance market efficiency, preserve tissue bank margins by eliminating intermediaries, and expand access to best-fit allografts. Its technology integrates with existing systems, facilitating adoption and potentially reshaping competitive dynamics in the tissue banking supply chain.
- The platform's neutral exchange model seeks to enhance market efficiency and preserve tissue bank margins by eliminating intermediaries.
- AlloPort's strategy focuses on broad adoption by integrating with existing tissue bank inventory systems, streamlining procurement.
PhD Lens: Clinical and outcomes impact
AlloPort introduces a B2B procurement platform designed to enhance access to allografts for surgical teams. By centralizing lot-level listings and ensuring traceability, the system supports critical safety measures like recall readiness and accreditation visibility. This aims to improve the selection of best-fit allografts, potentially optimizing procedural requirements and patient outcomes through better graft matching and supply chain transparency.
- The platform enhances allograft safety and quality assurance through features like lot/UDI traceability, recall readiness, and accreditation visibility.
- It aims to improve clinical utility by providing surgeons expanded access to best-fit allografts tailored to procedural requirements and patient anatomy.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.